[Federal Register Volume 76, Number 236 (Thursday, December 8, 2011)]
[Notices]
[Pages 76744-76745]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2011-31556]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Prospective Grant of Exclusive License: Use of Agents Targeting
Thrombospondin-1 and CD47 To Treat Radiation-Induced Damage and Enhance
the Effectiveness of Radiotherapy in Cancer Patients
AGENCY: National Institutes of Health, Public Health Service, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: This is a notice, in accordance with 35 U.S.C. 209(c)(1) and
37 CFR 404.7(a)(1)(i), that the National Institutes of Health (NIH),
Department of Health and Human Services (HHS), is contemplating the
grant of a worldwide exclusive license, to practice the inventions
embodied in U.S. Provisional Patent Application No. 60/850,132, filed
October 6, 2006, now abandoned (HHS Ref. No. E-227-2006/0-US-01); U.S.
Provisional Patent Application No. 60/864,153, filed November 02, 2006,
now abandoned (HHS Ref. No. E-227-2006/1-US-01); U.S. Provisional
Patent Application No. 60/888,754, filed February 07, 2007, now
abandoned (HHS Ref. No. E-227-2006/2-US-01); U.S. Provisional Patent
Application No. 60/910,549, filed April 06, 2007, now abandoned (HHS
Ref. No. E-227-2006/3-US-01); U.S. Provisional Patent Application No.
60/956,375, filed August 16, 2007, now abandoned (HHS Ref. No. E-227-
2006/4-US-01); PCT Patent Application No. PCT/2007/080647, filed
October 5, 2007, now abandoned (HHS Ref. No. E-227-2006/5-PCT-01); U.S.
Patent Application No. 12/444,364, filed April 3, 2009 (HHS Ref. No. E-
227-2006/5-US-02); Canadian Patent Application No. 2,665,287, filed
October 5, 2007 (HHS Ref. No. E-227-2006/5-CA-03); Australian Patent
Application No. 2007319576, filed October 5, 2007 (HHS Ref. No. E-227-
2006/5-AU-04); European Patent Application No. 07868382.8, filed
October 5, 2007 (HHS Ref. No. E-227-2006/5-EP-05); U.S. Provisional
Patent Application No. 61/086,991, filed August 7, 2008, now abandoned
(HHS Ref. No. E-153-2008/0-US-01); PCT Patent Application No. PCT/2009/
052902, filed August 5, 2009, now abandoned (HHS Ref. No. E-153-2008/0-
PCT-02); U.S. Patent Application No. 13/057,447, filed February 3, 2011
(HHS Ref. No. E-153-2008/0-US-06); Canadian Patent Application No.
2732102 filed August 5, 2009 (HHS Ref. No. E-153-2008/0-CA-043);
Australian Patent Application No. 2009279676, filed August 5, 2009 (HHS
Ref. No. E-153-2008/0-AU-03); and European Patent Application No.
09791202.6, filed August 5, 2009 (HHS Ref. No. E-153-2008/0-EP-08),
entitled ``Prevention of Tissue Ischemia, Related Methods and
Compositions,'' and ``Radioprotectants Targeting Thrombospondin-1 and
CD47,'' to Radiation Control Technologies, Inc., a company incorporated
under the laws of the State of Delaware having its headquarters in
Rockville, Maryland. The United States of America is the assignee of
the rights of the above inventions. The prospective exclusive license
territory may be ``worldwide,''
[[Page 76745]]
and the field of use may be limited to: (1) The use of morpholino
oligonucleotides that reduce expression of CD47 in combination with
radiotherapy, to treat or prevent cancers in humans; and (2) the use of
morpholino oligonucleotides that reduce expression of CD47 to treat or
prevent radiation exposure damage in humans.
DATES: Only written comments and/or applications for a license received
by the NIH Office of Technology Transfer on or before January 9, 2012
will be considered.
ADDRESSES: Requests for a copy of the patent application, inquiries,
comments and other materials relating to the contemplated license
should be directed to: Suryanarayana (Sury) Vepa, Ph.D., J.D., Office
of Technology Transfer, National Institutes of Health, 6011 Executive
Boulevard, Suite 325, Rockville, MD 20852-3804; Telephone: (301) 435-
5020; Facsimile: (301) 402-0220; Email: [email protected]. A signed
confidentiality nondisclosure agreement will be required to receive
copies of any patent applications that have not been published or
issued by the United States Patent and Trademark Office or the World
Intellectual Property Organization.
SUPPLEMENTARY INFORMATION: The present inventions provide for
compositions and methods for preventing and/or reducing tissue ischemia
and/or tissue damage due to ischemia, increasing blood vessel diameter,
blood flow and tissue perfusion in the presence of vascular disease, by
suppressing CD47 and/or blocking TSP1 and/or CD47 activity or
interaction. The present inventions also provide for the use of
morpholinos, peptides and antibodies that block the TSP1/CD47 signaling
pathway as radioprotectants for normal tissue, radioenhancers for tumor
tissue, and as protectants of normal tissue from damage caused by
radiation exposure.
The prospective exclusive license will be royalty bearing and will
comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7.
The prospective exclusive license may be granted unless, within thirty
(30) days from the date of this published notice, NIH receives written
evidence and argument that establishes that the grant of the license
would not be consistent with the requirements of 35 U.S.C. 209 and 37
CFR 404.7.
Properly filed competing applications for a license filed in
response to this notice will be treated as objections to the
contemplated license. Comments and objections submitted in response to
this notice will not be made available for public inspection, and, to
the extent permitted by law, will not be released under the Freedom of
Information Act, 5 U.S.C. 552.
Dated: December 2, 2011.
Richard U. Rodriguez,
Director, Division of Technology Development and Transfer, Office of
Technology Transfer, National Institutes of Health.
[FR Doc. 2011-31556 Filed 12-7-11; 8:45 am]
BILLING CODE 4140-01-P